AstraZeneca gets US FDA nod for FARXIGA to treat chronic kidney disease
In DAPA-CKD Phase III trial, FARXIGA demonstrated reduction in the risk of the composite of worsening of renal function, end-stage…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
DAPA-CKD trial
Diabetes drug, Dapagliflozin shows benefits in patients with CKD
The drug, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular (CV)…